Innate Pharma (IPHA)
NASDAQ:IPHA
Earnings Data
Report Date
Sep 10, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call featured multiple meaningful clinical and regulatory milestones (FDA clearance for lacutamab Phase III, completed PACIFIC-9 enrollment, encouraging early IPH4502 data, and high-value partnership milestone potential) and demonstrated cost discipline with lower R&D spend. Offsetting these positives are material near-term financing and execution risks: modest reported revenue (EUR 9M), a high burn rate (EUR 63M operating expenses), and a limited cash runway (EUR 44.8M through Q3 2026) that makes initiation of late-stage programs dependent on partner deals or other financing. Clinical data are promising but still early and need confirmation. Overall, the company shows strong programmatic momentum and partnership upside, but material funding and timing risks balance that optimism.Company Guidance
Regulatory Progress for Lacutamab
FDA cleared the TELLOMAK-3 Phase III protocol; lacutamab has Breakthrough Therapy Designation (relapsed/refractory Sezary syndrome), Fast Track, PRIME and Orphan Drug Designations. TELLOMAK-3 initiation is planned for H2 2026 (financing under discussion).
Commercial Opportunity for CTCL
Addressable U.S. population estimated at ~300 incident Sezary Syndrome patients/year (prevalence ~1,000) and ~3,000 incident Mycosis Fungoides patients/year (prevalence ~12,000). Management projects an initial Sezary market opportunity up to $150M expanding to >$500M across second-line Sezary + MF, with mogamulizumab as a $300M product in 2025 (projected $350M in 2026, ~+16.7%).
IPH4502 Early Clinical Activity and Differentiation
First-in-human Phase I is progressing; MTD established, cohorts enriched at pharmacologically active doses, and preliminary antitumor activity observed (including urothelial cancer post-enfortumab vedotin). Program is differentiated by exatecan payload, hydrophilic/cleavable linker and activity in low/heterogeneous Nectin-4 models—supporting potential best-in-class positioning.
Monalizumab Phase III (PACIFIC-9) Enrollment Complete
AstraZeneca-led PACIFIC-9 completed enrollment (~999 patients randomized 1:1:1) comparing durvalumab +/- monalizumab or oleclumab; primary PFS readout expected in H2 2026 — a major near-term clinical catalyst.
IPH5201 Progress and Scientific Visibility
IPH5201 (anti-CD39) MATISSE Phase II interim analysis (first 40 patients of up to 70) selected for oral presentation at AACR — increases visibility and may inform AstraZeneca opt-in decisions in this collaboration.
Partnerships and Upside Milestones
Partnerships with AstraZeneca include significant milestone potential: monalizumab up to $1.275B (already received $450M; $825M remaining) and IPH5201 up to $885M (already received $60M; $825M remaining). Structures include royalties and potential 50% profit share/co-promotion in Europe if Innate co-funds Phase III.
Cost Discipline and Reduced R&D Spend
Operating expenses totaled EUR 63M in 2025 with R&D representing 73% (EUR 43.6M). R&D spending decreased by 16% year-over-year, attributed to study maturity and lower staff/consulting costs (partially offset by restructuring charges).
IPHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IPHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 26, 2026 | $1.28 | $1.25 | -2.34% |
Sep 17, 2025 | $2.08 | $2.05 | -1.44% |
Mar 27, 2025 | $1.81 | $1.97 | +8.84% |
Sep 12, 2024 | $2.36 | $2.28 | -3.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Innate Pharma (IPHA) report earnings?
Innate Pharma (IPHA) is schdueled to report earning on Sep 10, 2026, Before Open (Confirmed).
What is Innate Pharma (IPHA) earnings time?
Innate Pharma (IPHA) earnings time is at Sep 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPHA EPS forecast?
IPHA EPS forecast for the fiscal quarter 2026 (Q2) is -0.33.